Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California. more
Time Frame | CERO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -47.31% | 0.31% | -1.26% |
1-Month Return | -46.27% | 0.6% | -4.16% |
3-Month Return | -72.32% | -9.44% | -0.46% |
6-Month Return | -85.8% | -5.15% | 3.58% |
1-Year Return | -99.75% | 0.33% | 22.47% |
3-Year Return | -99.72% | 4.53% | 25.13% |
5-Year Return | -99.72% | 35.98% | 77.7% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Profit | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Margin | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Operating Expenses | 332.03K | 2.91M | 2.93M | [{"date":"2021-12-31","value":11.32,"profit":true},{"date":"2022-12-31","value":99.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (332.03K) | (2.91M) | (2.93M) | [{"date":"2021-12-31","value":-33203000,"profit":false},{"date":"2022-12-31","value":-290544000,"profit":false},{"date":"2023-12-31","value":-293298500,"profit":false}] | ||
Total Non-Operating Income/Expense | 1.09M | 2.98M | - | [{"date":"2021-12-31","value":36.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Pre-Tax Income | (332.42K) | (68.58K) | (2.44M) | [{"date":"2021-12-31","value":-33241500,"profit":false},{"date":"2022-12-31","value":-6857700,"profit":false},{"date":"2023-12-31","value":-244141400,"profit":false}] | ||
Income Taxes | (16.87K) | 599.16K | 94.82K | [{"date":"2021-12-31","value":-2.82,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":15.83,"profit":true}] | ||
Income After Taxes | (315.55K) | (667.74K) | - | [{"date":"2021-12-31","value":-31554700,"profit":false},{"date":"2022-12-31","value":-66773600,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income From Continuous Operations | (10.63M) | (11.83M) | - | [{"date":"2021-12-31","value":-1062962000,"profit":false},{"date":"2022-12-31","value":-1182911600,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (315.55K) | (667.74K) | (2.54K) | [{"date":"2021-12-31","value":-31554700,"profit":false},{"date":"2022-12-31","value":-66773600,"profit":false},{"date":"2023-12-31","value":-253623,"profit":false}] | ||
EPS (Diluted) | (0.01) | (0.06) | (0.38) | [{"date":"2021-12-31","value":-1.37,"profit":false},{"date":"2022-12-31","value":-5.64,"profit":false},{"date":"2023-12-31","value":-37.91,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
CERO | |
---|---|
Cash Ratio | 0.36 |
Current Ratio | 0.39 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CERO | |
---|---|
ROA (LTM) | -45.28% |
ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CERO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.57 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.57 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CERO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
CERo Therapeutics Holdings, Inc. Common Stock (CERO) share price today is $2.8
Yes, Indians can buy shares of CERo Therapeutics Holdings, Inc. Common Stock (CERO) on Vested. To buy CERo Therapeutics Holdings, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CERO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of CERo Therapeutics Holdings, Inc. Common Stock (CERO) via the Vested app. You can start investing in CERo Therapeutics Holdings, Inc. Common Stock (CERO) with a minimum investment of $1.
You can invest in shares of CERo Therapeutics Holdings, Inc. Common Stock (CERO) via Vested in three simple steps:
The 52-week high price of CERo Therapeutics Holdings, Inc. Common Stock (CERO) is $1280. The 52-week low price of CERo Therapeutics Holdings, Inc. Common Stock (CERO) is $2.83.
The price-to-earnings (P/E) ratio of CERo Therapeutics Holdings, Inc. Common Stock (CERO) is
The price-to-book (P/B) ratio of CERo Therapeutics Holdings, Inc. Common Stock (CERO) is 0.00
The dividend yield of CERo Therapeutics Holdings, Inc. Common Stock (CERO) is 0.00%
The market capitalization of CERo Therapeutics Holdings, Inc. Common Stock (CERO) is $7.28M
The stock symbol (or ticker) of CERo Therapeutics Holdings, Inc. Common Stock is CERO